NANCY WEIGEL to Dose-Response Relationship, Drug
This is a "connection" page, showing publications NANCY WEIGEL has written about Dose-Response Relationship, Drug.
Connection Strength
0.128
-
1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology. 2010 Apr; 151(4):1409-17.
Score: 0.061
-
A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol. 2002 Dec; 16(12):2692-705.
Score: 0.037
-
Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem. 2006 Jul 01; 98(4):770-88.
Score: 0.012
-
Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res. 2004 Dec 01; 10(23):8018-27.
Score: 0.011
-
Species, interindividual, and tissue specificity in endocrine signaling. Environ Health Perspect. 1999 Aug; 107 Suppl 4:619-24.
Score: 0.007